With the aim of driving strategic partnerships and unlocking the value of its scientific assets in the field of Alzheimer’s prevention, the BBRC is adding a key new position to its organizational structure.
Dr. Montserrat Bosch Grau takes on this role as Business Development Director within Scientific Business Developer, bringing more than twenty years of experience spanning neuroscience research, preclinical drug development and science-industry partnerships. She holds a PhD in Biochemistry and Molecular Biology and has developed her research career at the CNRS, Institut Curie and Institut Pasteur in Paris, where she worked on cellular neurobiology and the mechanisms underlying the degeneration of neurosensory cells in the brain, retina and inner ear. She subsequently headed the preclinical department at the biotechnology company Sensorion (Montpellier) for five years, leading gene therapy and small-molecule programmes through to the clinical stage.
Until now, she served as Chief Business Officer at the Occitanie Biotherapy and Bioproduction Integrator (OBBI, Inserm), an initiative established under the France 2030 investment plan to bring the production of organoids and extracellular vesicles into the service of advanced therapies. There, she led the development of the integrator from its inception: launching a multisite consortium between Montpellier and Toulouse, establishing the Inserm service unit that supports it, and developing its portfolio of industrial, hospital and academic partners.
In this cross-functional role, Dr. Bosch Grau will lead the strategy for collaboration and access to the BBRC’s major scientific platforms: Neuroimaging, Fluid Biomarkers, Data (including the BioAIData platform), and the Clinical Trials Unit. Her mission is to translate these capabilities into clear collaboration proposals for three types of partners: the pharmaceutical and biotechnology industries, research centres and academic consortia, and hospitals and clinical networks.
With this strategy, the centre is consolidating a flexible access and open collaboration model aimed at accelerating biomarker validation, the development of new therapies, and the application of artificial intelligence tools and computational models. This integrated approach marks a new stage in bridging the gap between basic science, clinical data from real-world cohorts, and industrial innovation, ensuring a direct impact on the prevention and treatment of neurodegenerative diseases. "Our goal is to put the BBRC’s cutting-edge scientific platforms and our real-world clinical data at the service of global partnerships with the right partners—companies, research centres and hospitals. We want to transform the excellence of our capabilities into competitive value propositions that accelerate the prediction, prevention and treatment of Alzheimer’s disease," highlights Dr. Montserrat Bosch Grau.